JensCare-B(09877): JensRoboSiasun Robot & Automation assisted TTVR system completes the first clinical study in humans.
Jianshi Technology-B (09877) announced that the company has successfully completed the first clinical study of the iJensRobo robot-assisted transcatheter tricuspid valve replacement (TTVR) system.
JENSCARE-B (09877) Announcement: Our company has successfully completed the first clinical study using the iJensRoboSiasun Robot&Automation assisted transcatheter tricuspid valve replacement (TTVR) system.
Recently, our company completed the first patient clinical study using the iJensRoboSiasun Robot&Automation assisted TTVR system in Hong Kong. The surgery utilized our iJensRoboSiasun Robot&Automation assisted TTVR system to successfully implant the LuX-Valve Plus valve in a patient with severe tricuspid valve regurgitation. Post-surgery ultrasound showed complete disappearance of tricuspid regurgitation, no perivalvular leak, and good stability of the LuX-Valve Plus artificial valve.
This system is an innovative Siasun Robot&Automation assisted intervention platform of our company, aiming to provide more precise, stable, and controllable support for TTVR surgery. The iJensRoboSiasun Robot&Automation assisted TTVR system combines high-precision motion control, active safety restraint mechanisms, and intelligent navigation technology to achieve stable and precise instrument manipulation, supporting the safety and reliability of critical operational steps.
Compared to traditional manual operation methods, the iJensRoboSiasun Robot&Automation assisted TTVR system helps to reduce potential impacts caused by minor hand tremors, differences in operating range, and spatial positioning deviations. By providing structured guidance for critical operational steps, it enhances the stability and consistency of operations to some extent. At the same time, the system, combined with real-time control and safety limiting mechanisms, helps to reduce risks such as instrument drift, misoperations, and unstable operation paths during complex operation processes, and reduces reliance on the operator's personal experience to some extent.
In terms of system architecture, this platform adopts a master-slave control design to reduce the operator's radiation exposure during surgery and improve occupational health risks. Additionally, the system also integrates remote operation functions, with potential support for cross-regional surgical collaboration and remote training.
Related Articles

HK Stock Market Move | CRRC Corporation(01766) fell more than 7% after its performance announcement. Its annual net profit increased by more than 6% year-on-year, but the downturn in the urban rail industry may drag down its performance.

HK Stock Market Move | ANGELALIGN (06699) rose nearly 9% in intraday trading, with adjusted annual net profit increasing by nearly 63% year-on-year, reaching a total number of cases of over 532,400.

CICC: Maintains an "outperform" rating on KINGSOFT (03888), but lowers the target price to HK$32.
HK Stock Market Move | CRRC Corporation(01766) fell more than 7% after its performance announcement. Its annual net profit increased by more than 6% year-on-year, but the downturn in the urban rail industry may drag down its performance.

HK Stock Market Move | ANGELALIGN (06699) rose nearly 9% in intraday trading, with adjusted annual net profit increasing by nearly 63% year-on-year, reaching a total number of cases of over 532,400.

CICC: Maintains an "outperform" rating on KINGSOFT (03888), but lowers the target price to HK$32.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


